Health Condition 1: null- Severe exacerbation of Chronic Obstructive Pulmonary Disease requiring hospitalization.
Conditions
Interventions
Intervention1: Inhaled budesonide plus standard treatment for COPD: Inhaled budesonide 400 micrograms twice daily for eight weeks along with standard treatment for COPD.
Control Intervention1: Placebo
Sponsors
PSG Institute of Medical Sciences and Research
Eligibility
Inclusion criteria
Inclusion criteria: Age 40 years and above. Smoking history with more than 10 pack years. Physician diagnosed severe exacerbation of COPD requiring hospitalization. Willing to participate in the study adhering to its protocol.
Exclusion criteria
Exclusion criteria: History suggestive of asthma. History of past or coexisting malignancy, connective tissue disorders and other chronic inflammatory disorders. Coexisting poorly controlled diabetes mellitus (HbA1C > 8.5%), pneumonia and active tuberculosis. Subjects requiring ICU stay with or without life support for management of severe exacerbation of COPD. Mental status not competent enough to consent for the study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Changes in lipids level, systemic inflammation oxidative stress and anti-inflammatory function of HDL during acute exacerbation of COPD and recovery to stable state.Timepoint: eight weeks | — |
Secondary
| Measure | Time frame |
|---|---|
| dynamics of PON1 activity during AECOPD and after recovery to stable state.Timepoint: eight weeks;impact of inhaled corticosteroids on the systemic inflammation, oxidative stress and HDL function in COPD.Timepoint: eight weeks;Influence of PON1 activity with lipid peroxidation, systemic inflammation oxidative stress and HDL function in COPD.Timepoint: eight weeks | — |
Countries
India
Contacts
Public ContactRamalingam Sankaran
PSG Institute of Medical Sciences and Research
Outcome results
None listed